Serelaxin Is a More Efficacious Antifibrotic Than Enalapril in an Experimental Model of Heart Disease
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Serelaxin Is a More Efficacious Antifibrotic Than Enalapril in an Experimental Model of Heart Disease
Authors
Keywords
-
Journal
HYPERTENSION
Volume 64, Issue 2, Pages 315-322
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2014-05-28
DOI
10.1161/hypertensionaha.114.03594
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The pathogenesis of cardiac fibrosis
- (2013) Ping Kong et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Pathological Ventricular Remodeling
- (2013) Min Xie et al. CIRCULATION
- Relaxin decreases the severity of established hepatic fibrosis in mice
- (2013) Robert G. Bennett et al. LIVER INTERNATIONAL
- Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial
- (2012) John R Teerlink et al. LANCET
- Mechanisms of fibrosis: therapeutic translation for fibrotic disease
- (2012) Thomas A Wynn et al. NATURE MEDICINE
- Relaxin Signals through a RXFP1-pERK-nNOS-NO-cGMP-Dependent Pathway to Up-Regulate Matrix Metalloproteinases: The Additional Involvement of iNOS
- (2012) Bryna Suet Man Chow et al. PLoS One
- H3 Relaxin Demonstrates Antifibrotic Properties via the RXFP1 Receptor
- (2011) Mohammed Akhter Hossain et al. BIOCHEMISTRY
- Relaxin remodels fibrotic healing following myocardial infarction
- (2011) Chrishan S Samuel et al. LABORATORY INVESTIGATION
- Monitoring cardiac fibrosis: a technical challenge
- (2011) S. de Jong et al. Netherlands Heart Journal
- Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey
- (2011) Richard Kones Drug Design Development and Therapy
- Targeting Fibrosis for the Treatment of Heart Failure: A Role for Transforming Growth Factor-β
- (2010) Amanda J Edgley et al. Cardiovascular Therapeutics
- Antifibrotic Properties of Relaxin:In VivoMechanism of Action in Experimental Renal Tubulointerstitial Fibrosis
- (2010) Tim D. Hewitson et al. ENDOCRINOLOGY
- Reversal of Cardiac Fibrosis and Related Dysfunction by Relaxin
- (2009) Xiao-Jun Du et al. Annals of the New York Academy of Sciences
- Relaxin and its role in the development and treatment of fibrosis
- (2009) Robert G. Bennett Translational Research
- Relaxin Ameliorates Fibrosis in Experimental Diabetic Cardiomyopathy
- (2008) Chrishan S. Samuel et al. ENDOCRINOLOGY
- Relaxin inhibits renal myofibroblast differentiation via RXFP1, the nitric oxide pathway, and Smad2
- (2008) Ishanee Mookerjee et al. FASEB JOURNAL
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now